Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.
about
Quantitative proteomics in lung cancer.Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.Recent insights into human bronchial proteomics - how are we progressing and what is next?The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable
P2860
Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Recent mass spectrometry-based ...... lung cancer, COPD, and asthma.
@en
Recent mass spectrometry-based ...... lung cancer, COPD, and asthma.
@nl
type
label
Recent mass spectrometry-based ...... lung cancer, COPD, and asthma.
@en
Recent mass spectrometry-based ...... lung cancer, COPD, and asthma.
@nl
prefLabel
Recent mass spectrometry-based ...... lung cancer, COPD, and asthma.
@en
Recent mass spectrometry-based ...... lung cancer, COPD, and asthma.
@nl
P2093
P2860
P1476
Recent mass spectrometry-based ...... lung cancer, COPD, and asthma.
@en
P2093
Haruhiko Nakamura
Kiyonaga Fujii
Toshihide Nishimura
P2860
P304
P356
10.1080/14789450.2017.1304215
P577
2017-03-08T00:00:00Z